Mérieux Equity Partners acquires a significant minority stake in Health in Code, Spain's leading integrated clinical genetics platform, alongside Alantra Private Equity's continuation vehicle and Management.

Lyon/Paris, France – February 12th, 2026 - **Mérieux Equity Partners ("MxEP") is pleased to announce its investment in Health in Code ("HiC"), through its buyout fund, Mérieux Participations 4 ("MP4"). This investment aims to support and accelerate HiC's next phase of growth and international expansion.**

Founded in 2020 through the strategic combination of Health in Code, Imegen, Genycell Biotech, and later Genologica, HiC has become a leading player in genetic diagnostics and precision medicine. Headquartered in Valencia, Spain, the company has built an integrated model combining Next-Generation sequencing[1] (NGS)-based diagnostic services, genetic testing kits/panels, and proprietary bioinformatics and clinical interpretation. Thereby, HiC's solution accelerates and improves diagnostics for patients, providing rapid, high-confidence results that support more effective clinical decisions.

The company partners primarily with public hospitals, providing end-to-end genetic testing services from sample preparation, proprietary NGS panels and kits, or bioinformatics software, to the delivery of clinical reports. Furthermore, HiC has developed a differentiated commercial model through its Rental Reagent Program, under which it supports hospitals with sequencing workflows through long-term partnerships, bundling equipment access with consumables, its proprietary DataGenomics platforms, and related services.

Under Alantra PE's ownership, HiC has more than doubled its revenues from €24mn to more than €50mn, consolidated its leadership in the domestic market, successfully completed its integration, and scaled operations to approximately 200 employees, supporting healthcare professionals in more than 30 countries.

HiC was proactively identified through *MxEP's Dedicated Sector Work* in the genomics space. MxEP's investment will support HiC's next phase of growth by accelerating international expansion into key European markets, driving continued product innovation to meet evolving clinical needs, and continuing to improve operational efficiency by further integration and enhanced software platforms. In addition, targeted partnerships and selective strategic acquisitions could also facilitate market entry and broaden capabilities.

Theodor Wuppermann, Partner at MxEP: "Health in Code has built a uniquely integrated clinical genomics platform anchored in long-standing relationships with Spanish hospitals. We are excited to partner with Alantra and the management team to support HiC's next chapter of growth with a specific focus on international expansion."

Ángel Manotas, Managing Director at Alantra Private Equity: "The successful close of our first single-asset continuation vehicle marks an important strategic milestone for Alantra Private

[1]Next-generation sequencing (NGS) is a technology for determining the sequence of DNA or RNA to study genetic variation associated with diseases or other biological phenomena.

Equity. This transaction reflects our conviction in Health in Code as a high-quality asset with significant growth ahead. We believe this structure offers the best outcome for all stakeholders, allowing existing investors to triple their investment while enabling us to continue contributing to the company's growth trajectory. Our ambition is clear: to create a European leader in clinical genomics with €100mn in revenues within the next five years, driven by international expansion and strategic acquisitions."

The investment in Health in Code represents the 12th and last investment of MP4 (vintage 2021, €568m) and the first buyout investment in Spain. MxEP continues to demonstrate its commitment to fostering innovation in healthcare in Europe.

Banca March, a financial institution specialized in providing advisory services to family-owned businesses, corporate groups, and international Private Equity funds on their investments in Spain, has acted as financial advisor to Mérieux Equity Partners.

About Mérieux Equity Partners - www.merieux-partners.com
Founded in 2009, Mérieux Equity Partners ("MxEP") is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.6bn of AuM.

About Health in Code - www.healthincode.com
Health in Code ("HiC") is a Spain-based clinical genomics platform headquartered in Valencia. HiC provides NGS-based diagnostic services, genetic testing products and proprietary bioinformatics and clinical interpretation to support hospitals and clinicians with actionable results across a range of indications.

About Alantra and Alantra Private Equity - www.alantra.com
Alantra is an independent global mid-market financial services firm that provides investment banking and asset management services to companies, families, and investors in the mid-market segment. The Group has over 500 professionals across Europe, the U.S., Latin America, Asia, and the Middle East.
In Alternative Asset Management, Alantra offers its clients unique access to a wide range of investment strategies in five highly specialized asset management classes (private equity, active funds, private debt, energy, and venture capital). As of 30 September 2025, assets under management from consolidated businesses stood at €2.7bn, while those managed by firms in which the Group holds a strategic stake amounted to €14.2bn.
Alantra Private Equity is a pioneer in the Iberian private equity market with more than 30 years of experience and investments of more than €1.5bn. Since 1990, Alantra Private Equity has led investments in over 120 assets, including add-ons, and has completed more than 50 exits.

List of participants
-Health in Code:
-Alantra: Ángel Manotas, Juan Luis Torres, Riccardo Campagnola, Maria Benjumeda

[1]Next-generation sequencing (NGS) is a technology for determining the sequence of DNA or RNA to study genetic variation associated with diseases or other biological phenomena.

-Mérieux Equity Partners: Theodor Wuppermann, Romain Blache, Leo Reimann

MxEP's buy-side advisors
-Legal: DLA Piper
-Strategy: L.E.K.
-M&A: Banca March
-Financial and Tax: 8Advisory

Press contacts

CTCom (France):
Sibylle Descamps / sibylle.descamps@ct-com.com
Laure Schlagdenhauffen / laure.schlagdenhauffen@ct-com.com

MHP (UK/International):
James McFarlane / james.mcfarlane@mhpgroup.com
Matthew Taylor / matthew.taylor@mhpgroup.com

[1]Next-generation sequencing (NGS) is a technology for determining the sequence of DNA or RNA to study genetic variation associated with diseases or other biological phenomena.